McNicoll, Lewis & Vlak Reiterates Inhibitex Buy, $7 PT

McNicoll, Lewis & Vlak reiterated its Inhibitex INHX Buy rating and $7 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We reiterate our BUY rating and $7 price target. INHX plans to actively engage the FDA in designing a Phase IIb study of FV-100 based on patient reported outcomes of post-herpetic neuralgia (PHN). We expect the study to begin in 2012." Shares of Inhibitex were trading at $3.32 at the time of posting, down 0.52% from Monday's market close.